Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: Amgen Inc. (AMGN)

AMGN insider trades (13 months) →

$461.26 −0.90% vs. previous close · Market cap $249.37B

Today's multi-factor rank: 165 of 461 · see the ranking

Quant500 Scores
Momentum
6.5/10
Value
4.0/10
Growth
4.8/10
Quality
5.2/10
Multifactor
5.1/10

Market and Valuation

Price & Market

Prev Close Price:$465.45
Open:$463.38
Day's Low:$460.15
Day's High:$467.02
Bid / Ask:-
Market Cap:249.37B
Enterprise Value:294.95B

52-Week Range

52-Week Low:$294.48
52-Week High:$475.65
Current position in 52-week range
52w Low-52w High
50-Day Avg:$420.49
200-Day Avg:$375.46

Volume

Volume Today:2,351,852
Avg Volume (3m):2,795,459
Avg Volume (10d):2,616,230
52-Week Change:+56.88%
vs S&P 500, 52 weeks:-
Beta:0.42

Valuation Multiples

P/E (trailing):28.65

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

P/E (forward):18.83
PEG Ratio:2.78
Price / Book:21.33
Price / Sales (TTM):6.55
EV / Revenue:7.74
EV / EBITDA:17.08

Dividends

Current yield:2.17%
Annual Dividend Rate:$10.08
Dividend Trailing:$9.80
Yield Trailing:2.11%
5-Year Avg Yield:2.99%
Payout Ratio:60.87%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):38.09B
Gross Profit:27.39B
EBITDA:17.27B
Net Income (TTM):8.74B
Rev Growth (YoY):+9.50%
Earnings Growth (YoY):+64.90%
Quarterly earnings growth (YoY):+65.90%

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$16.10

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$24.50
Revenue Per Share:$70.68
Cash Per Share:-
Book Value:$21.62
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:13.99B
Total Debt:57.30B
Net Debt (Debt - Cash):43.31B
Debt / Equity:490.28%
Current Ratio:1.37
Quick Ratio:0.95

Cash Flows

Operating Cash Flow:12.48B
Free Cash Flow (FCF):8.65B
FCF Yield (FCF / Market Cap):-
Enterprise Value:294.95B
EV / Revenue:7.74
EV / EBITDA:17.08

Profitability

ROE (Return on Equity):91.47%
ROA (Return on Assets):8.67%
P/E (trailing):28.65
P/E (forward):18.83
Price / Book:21.33
PEG Ratio:2.78
52-Week Change:+56.88%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$16.10

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$24.50
P/E (forward):18.83
PEG Ratio:2.78

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$70.68
Cash Per Share:-
Book Value:$21.62

Cash Flows (TTM)

Free Cash Flow:8.65B
Operating Cash Flow:12.48B
EBITDA:17.27B
Total Revenue (TTM):38.09B
Net Income (TTM):8.74B
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:540,632,005
Float (free shares):539,156,080
Short interest (shares):13,378,638
Short % of float:-
Short Ratio (days to cover):4.35
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

Amgen Inc. (AMGN) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
8-K2026-10-27View filing ↗
10-Q2026-08-05View filing ↗
8-K2026-08-04View filing ↗
8-K2026-07-31View filing ↗
11-K2026-06-11View filing ↗
8-K2026-05-20View filing ↗
8-K2026-05-19View filing ↗
10-Q2026-05-01View filing ↗
8-K2026-04-30View filing ↗
8-K2026-04-22View filing ↗

Company and Executive Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

General Information

Headquarters:United States
City:Thousand Oaks
Employees:31,500
Sector:Healthcare
Industry:Drug Manufacturers - General
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Robert A. BradwayChairman & CEO626.69M
Mr. Murdo GordonExecutive Vice President of Global Markets and Policy583.22M

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Amgen Inc. (AMGN): Quantitative Analysis

Amgen Inc. (AMGN) — Healthcare — Drug Manufacturers - General. AMGN is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, AMGN has returned +43.2% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

AMGN ranks 165 of 461 on today's multifactor score, and 20 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.89, ranked 74 of 494); its weakest is value (Z -0.63, ranked 428 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor0.060165 of 461
Momentum0.88974 of 494 ↓6
Value-0.629428 of 489
Quality0.130159 of 468
Growth-0.149234 of 489

Market data

MetricValue
Price$461.26
Market Cap249.37B
P/E28.65
Revenue (last 12 months)38.09B
Price / book21.33
Book value per share$21.62
52-week range$294.48 – $475.65
Dividend yield2.17%
Beta0.42
Average volume2,795,459
Shares outstanding540.63M
Short interest (% of float)2.48% (as of Oct 15, 2026)

When does AMGN report earnings? 11 of its last 12, after the close →

What are AMGN insiders doing? 106 transactions filed with the SEC, of them 10 sells, the last one on Aug 13, 2026 →

AMGN latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All AMGN filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Amgen (AMGN)

When does Amgen report earnings?

According to Nasdaq's public calendar (checked on Nov 4, 2026), Amgen will report its next earnings on Nov 3, 2026, after the US market closes. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 11 after the close and 1 before the open (SEC filings through Aug 4, 2026). AMGN earnings dates and times, quarter by quarter →

What is Amgen's P/E ratio?

Amgen's P/E (price over earnings per share for the last twelve months) is 28.6 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Amgen is below its sector median. Healthcare stocks, company by company →

Where does Amgen rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Amgen ranks 165 of 461, and 20 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Amgen insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of Amgen shares from August 2025 through Nov 3, 2026. The latest sale was on Aug 13, 2026, by an officer, for $521k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 10 sales by directors, officers and large shareholders. All AMGN insider trades →

Does Amgen pay a dividend?

Yes. Its dividend yield is 2.17% at the Nov 3, 2026 close (annual dividend of $10.08 per share). The next announced ex-dividend date is Nov 20, 2026.

What sector is Amgen in, and which index?

Amgen is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity